Clinical Trial Update: A First in Human Study of the Safety, Tolerability and Pharmacokinetics of PRV-002 in Healthy Volunteers [Phase 1]

View source ↗

Summary

This first-in-human Phase 1 study assessed safety, tolerability, and pharmacokinetics of PRV-002 in healthy volunteers and has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Traumatic Brain Injury

Drugs mentioned

• PRV-002

Snippet

Sponsor: Odyssey Group International, Inc. | Conditions: Traumatic Brain Injury (TBI) | Phase 1 | Status: COMPLETED